Antibiotic Therapy In Respiratory Tract Infections
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France10 sites in 1 countryChoose a country to see its sites
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 310 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Predetermined treatment duration
- Variable treatment duration
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Patient aged 18 years or more
- Has given written informed consent
- Affiliated to Health insurance
- Is able to take oral treatment
- Presenting with suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:; Fever (temperature > 38°C); Dyspnea; Cough; Production of purulent sputum; Crackles; Radiological evidence of a new infiltrate (on chest X-ray or CT scan)
- In need for antibiotic treatment targeting respiratory tract, according to the physician in charge
- No other site of infection besides respiratory
Who cannot take part
- Baseline oxygen saturation < 90% or home oxygen therapy
- More than 24 hours of antibiotics prior to consultation
- Any other infection necessitating concomitant antibiotic treatment
- Concomitant steroid treatment only for patients treated with fluoroquinolones antibiotics
- Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, arterial hypertension, atherosclerosis only for patients treated with fluoroquinolones antibiotics
- Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)
- Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, immunosuppressive treatments or corticosteroids (prednisolone equivalent) > 10 mg/day, transplant, myeloma, lymphoma, known HIV and CD4<400/mm3, sickle-cell disease, Child-Pugh class C cirrhosis)
- All subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation:
- Hospitalization following consultation
- Suspected or confirmed legionellosis
- Atrial fibrillation / constitutive tachycardia
- Patients for whom the investigator plans to prescribe a fluoroquinolone (including levofloxacin) for the treatment of community-acquired pneumonia
- Contraindications to the study antibiotics
- Pregnancy
- Breastfeeding
- Life expectancy < 1 month
- Patient under legal guardianship or without healthcare coverage
- Homeless patient
- Patient enrolled in another interventional clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary aim: to demonstrate that stopping antibiotic treatment in patients diagnosed with acute community acquired pneumonia (CAP) based on clinical response has a non-inferior efficacy 15 days after start of treatment, compared to a conventional predetermined duration left to the physician's judgement, in adults treated in the community setting.
Read full original descriptionShow less
Secondary aims: To compare the 2 study arms on:
1. Clinical success at late follow up (Day 30), 2. Duration of antibiotic treatment, 3. Frequency and severity of adverse events, 4. Patient's pneumonia symptoms and quality of life.
The 2 groups in the trial
- Physician's prescriptionExisting treatment, for comparison
Antibiotic treatment duration according to physician, following the French national guidelines (www.has-sante.fr/upload/docs/application/pdf/2024-12/reco362\_fiche\_memo\_\_durees\_antibiotherapies\_pac\_adulte\_mel\_dec\_2024.pdf )
Treatment: Predetermined treatment duration
- Duration according to stabilityTreatment being tested
Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%). Minimum of duration of antibiotic treatment: 3 days.
Treatment: Variable treatment duration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Controlled Randomized, Open Label, Multicenter, Non-inferiority Trial Evaluating an Individualized Antibiotic Duration Treatment Based on Patient Clinical Response, Evaluated Through Connected Devices, for Community Acquired Pneumonia in the Community Setting
- Record updated
- 12 November 2026